Curanex Pharmaceuticals Inc filed its quarterly report on Form 10-Q with the SEC on November 13, 2026, covering the three and nine months ended September 30, 2026, disclosing a net loss of $9,256,795 for the nine-month period and reporting total assets of $3,097,012.

Key Highlights

  • Nine-month net loss: The company reported a net loss of $9,256,795 for the nine months ended September 30, 2026, compared to $1,151,988 for the same period in 2025.
  • Quarterly net loss: Net loss for the three months ended September 30, 2026 was $2,815,597, versus $954,059 in the prior-year quarter.
  • R&D expenses: Research and development expenses totaled $6,802,466 for the nine months ended September 30, 2026, compared to $679,574 for the same period in 2025.
  • Cash position: Cash stood at $1,579,689 as of September 30, 2026, down from $4,973,134 as of December 31, 2025.
  • Reverse stock split: On August 20, 2026, the company effected a 1-for-20 reverse stock split of its outstanding shares of common stock.
  • Shares outstanding: As of November 13, 2026, the company had 1,568,216 shares of common stock outstanding, with a par value of $0.0001 per share.
  • Accumulated deficit: The accumulated deficit reached $14,104,350 as of September 30, 2026, compared to $4,847,555 as of December 31, 2025.

Curanex Pharmaceuticals: Financial Condition and Operating Results Through September 30, 2026

According to the filing, Curanex Pharmaceuticals Inc (NASDAQ:CURX) reported total operating expenses of $9,338,627 for the nine months ended September 30, 2026, a sharp increase from $1,146,437 for the comparable period in 2025. Research and development costs were the primary driver, rising to $6,802,466 from $679,574 year over year, while general and administrative expenses increased to $2,536,161 from $466,863 over the same span.

The company's balance sheet as of September 30, 2026 showed total assets of $3,097,012, down from $11,580,124 as of December 31, 2025. The filing disclosed that cash declined to $1,579,689 from $4,973,134 over that period, and prepaid expenses fell to $976,701 from $6,254,374. Total shareholders' equity was reported at $2,545,181, compared to $11,219,084 at year-end 2025. The company's accumulated deficit grew to $14,104,350 as of September 30, 2026.

The filing noted that on August 20, 2026, the company effected a 1-for-20 reverse stock split of its outstanding shares of common stock. All share and per share data in the quarterly report, including historical figures, have been retroactively adjusted to reflect this split, according to the filing. Net loss per common share on a basic and diluted basis was $1.86 for the three months ended September 30, 2026, and $6.38 for the nine months ended September 30, 2026, based on weighted average shares outstanding of 1,516,284 and 1,450,951, respectively, as adjusted for the reverse stock split. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

What Was Disclosed

Curanex Pharmaceuticals filed a Form 10-Q for the quarter ended September 30, 2026, disclosing a nine-month net loss of $9,256,795, a significant rise in research and development spending, reduced cash and total assets, and details of a 1-for-20 reverse stock split completed in August 2026.